首页> 外文期刊>Expert opinion on therapeutic targets >Targeting of extracellular proteases required for the progression of pancreatic cancer
【24h】

Targeting of extracellular proteases required for the progression of pancreatic cancer

机译:胰腺癌进展所需的细胞外蛋白酶的靶向

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death in the United States. its lethality is due, in large part, to its resistance to traditional chemotherapeutics. As a result, there is an enormous effort being put into basic research to identify proteins that are required for PDA progression so that they may be specifically targeted for therapy. Objective: To compile and analyze the evidence that suggests that extracellular proteases are significant contributors to PDA progression. Methods: We focus on three different extracellular protease subclasses expressed in PDA: metalloproteases, serine proteases and cathepsins. Based on data from PDA and other cancers, we suggest their probable roles in PDA. Results/conclusions: Of the proteases expressed in PDA, many appear to have overlapping functions, based on the substrates they process, making therapeutics complicated. Two protease families most likely to have unique, critical functions during tumor progression, and therefore strong potential as therapeutic targets, are the a disintegrin and metalloproteases (ADAMs) and the cathepsins.
机译:背景:胰腺导管腺癌(PDA)是美国癌症相关死亡的第四个主要原因。其致命性在很大程度上是其对传统化学治疗剂的抵抗力。结果,巨大的努力投入基本研究,以鉴定PDA进展所需的蛋白质,以便它们可以特别靶向治疗。目的:编制和分析表明细胞外蛋白酶是PDA进展的重要贡献者。方法:我们专注于PDA:金属蛋白酶,丝氨酸蛋白酶和组织丝表达的三种不同的细胞外蛋白酶亚类。根据PDA和其他癌症的数据,我们建议他们在PDA中的可能角色。结果/结论:在PDA中表达的蛋白酶,许多似乎具有重叠功能,基于它们的基材,使治疗剂复杂化。两种蛋白酶家族最容易在肿瘤进展过程中具有独特,关键功能,因此是作为治疗靶标的强大潜力,是解毒素和金属蛋白酶(ADAMS)和组织蛋白酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号